Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001306 | 1.00 | SHBG (0.50) | SHBGCTSKEPHX1CYP1A2TP53 | |
| SCHEMBL18656079 | 0.88 | SHBG (0.45) | SHBGCTSKTP53 | |
| SCHEMBL2985858 | 0.86 | SHBG (0.50) | SHBGCTSKEPHX1CYP1A2TP53 | |
| SCHEMBL3000784 | 0.79 | SHBG (0.41) | SHBGCTSKEPHX1CYP1A2TP53 | |
| SCHEMBL28402342 | 0.77 | SHBG (0.44) | SHBGEPHX1TP53 | |
| SCHEMBL11838850 | 0.77 | SHBG (0.44) | SHBGEPHX1CYP1A2TP53 | |
| SCHEMBL24622520 | 0.76 | SHBG (0.42) | SHBGCTSKEPHX1CYP1A2TP53 | |
| SCHEMBL5460788 | 0.76 | SHBG (0.42) | SHBGCTSKEPHX1CYP1A2TP53 | |
| SCHEMBL7392023 | 0.76 | SHBG (0.42) | SHBGCTSKEPHX1CYP1A2TP53 | |
| SCHEMBL2339293 | 0.76 | SHBG (0.42) | SHBGCTSKEPHX1CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772508-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | HTT, MAPT, HYPK | SHBG 1026/4885CTSK 3714/4885EPHX1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.